Trials / Completed
CompletedNCT01063829
Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- AiCuris Anti-infective Cures AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 60 mg AIC246 | Oral administration |
| DRUG | 120 mg AIC246 | Oral administration |
| DRUG | 240 mg AIC246 | Oral administration |
| OTHER | Placebo | Oral administration |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2011-10-01
- Completion
- 2011-12-01
- First posted
- 2010-02-05
- Last updated
- 2018-02-13
- Results posted
- 2018-02-13
Locations
24 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT01063829. Inclusion in this directory is not an endorsement.